FDA authorizes REGEN-COV for COVID-19 prevention in certain individuals; baricitinib without remdesivir
The Food and Drug Administration Friday authorized using the monoclonal antibody therapy REGEN-COV for prevention in certain children and adults who are not fully vaccinated against COVID-19 or not expected to mount an adequate immune response to vaccination.
FDA also authorized administering baricitinib (Olumiant) by itself to treat COVID-19 in hospitalized patients age 2 and older who require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation. The emergency use authorization previously required administering baricitinib with remdesivir (Veklury).
Related News Articles
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…